Laurent Paulhac

Insider

First SEC filing: Sept. 17, 2013 · Latest: Sept. 17, 2013

On this page

Insider at Companies where this person is a reporting insider.
Insider transactions Every share this person bought or sold, from Form 4 filings.
Derivatives Options and other derivative holdings reported by this person.
Compensation Executive pay disclosed in company proxy statements.

Insider at

CME selling Sept. 14, 2012

Insider transactions

0 buys (P) 0 sells (S) Net: $0 + 17 non-open-market transactions below last 12 months, based on the transactions shown below

Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted

17 other filings hidden

Date	Ticker	Code	Shares	Price	Value	Owned after	Δ own	A/D	vs now
Sept. 16, 2013	CME	A	3,048	—	—	16,715 Direct	+22.30%	Acquired	(price as of 2026-08-21)
Sept. 15, 2013	CME	F	369	$72.35	$26,697	14,526 Direct	-2.48%	Disposed	277.4% (price as of 2026-08-21)
Sept. 15, 2013	CME	F	383	$72.35	$27,710	14,143 Direct	-2.64%	Disposed	277.4% (price as of 2026-08-21)
Sept. 15, 2013	CME	F	476	$72.35	$34,439	13,667 Direct	-3.37%	Disposed	277.4% (price as of 2026-08-21)
Sept. 14, 2013	CME	F	319	$72.35	$23,080	14,895 Direct	-2.10%	Disposed	277.4% (price as of 2026-08-21)
March 15, 2013	CME	F	161	$63.14	$10,166	15,214 Direct	-1.05%	Disposed	332.5% (price as of 2026-08-21)
March 8, 2013	CME	A	1,752	—	—	15,375 Direct	+12.86%	Acquired	(price as of 2026-08-21)
Sept. 15, 2012	CME	F	502	$58.89	$29,563	13,623 Direct	-3.55%	Disposed	363.7% (price as of 2026-08-21)
Sept. 15, 2012	CME	F	375	$58.89	$22,084	14,125 Direct	-2.59%	Disposed	363.7% (price as of 2026-08-21)
Sept. 15, 2012	CME	F	391	$58.89	$23,026	14,500 Direct	-2.63%	Disposed	363.7% (price as of 2026-08-21)
Sept. 14, 2012	CME	A	3,716	—	—	14,891 Direct	+33.25%	Acquired	(price as of 2026-08-21)
Sept. 14, 2012	CME	S	1,000	$59.72	$59,720	11,175 Direct	-8.21%	Disposed	357.2% (price as of 2026-08-21)
Sept. 14, 2012	CME	S	2,585	$59.70	$154,324	12,175 Direct	-17.51%	Disposed	357.4% (price as of 2026-08-21)
Sept. 15, 2011	CME	A	1,124	—	—	1,124 Direct	—	Acquired	(price as of 2026-08-21)
Sept. 15, 2011	CME	A	912	—	—	2,952 Direct	+44.71%	Acquired	(price as of 2026-08-21)
Sept. 15, 2010	CME	A	2,724	—	—	2,724 Direct	—	Acquired	(price as of 2026-08-21)
Sept. 15, 2010	CME	A	1,212	—	—	2,040 Direct	+146.38%	Acquired	(price as of 2026-08-21)
Sept. 15, 2009	CME	A	1,672	—	—	1,672 Direct	—	Acquired	(price as of 2026-08-21)
Sept. 15, 2009	CME	A	828	—	—	828 Direct	—	Acquired	(price as of 2026-08-21)

P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding

Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.

Derivative holdings (Form 4 Table II)

Options, RSUs and convertible securities reported on Form 4 Table II.

Date	Ticker	Security	Underlying	Exercise price	Expiration	Shares	A/D
Sept. 15, 2011	CME	Non-Qualified Stock Option (right to buy)	Common Stock Class A (1,124)	$271.86	Sept. 15, 2021	1,124	Acquired
Sept. 15, 2010	CME	Non-Qualified Stock Option (right to buy)	Common Stock Class A (2,724)	$271.49	Sept. 15, 2020	2,724	Acquired
Sept. 15, 2009	CME	Non-Qualified Stock Option (right to buy)	Common Stock Class A (1,672)	$284.34	Sept. 15, 2019	1,672	Acquired

Exercise/conversion price is blank when not applicable (e.g. RSUs).

Compensation (DEF 14A)

Matched by name from proxy statements (DEF 14A) — verify against the filing.

CME

Fiscal year	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension change	Other	Total
2009	$335,077	$1,770,000	$235,434	—	$65,865	$4,093	$90,132	$2,699,067

Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.